Abstract
Background Widespread use of masks in the general population is being used in many countries for control of Covid-19. There has been reluctance on the part of the WHO and some governments to recommend this.
Methodology A basic model has been constructed to show the relative risk of aerosol from normal breathing in various situations together with the relative benefit from use of different masks.
Results The benefit from mask use between individuals is multiplicative not additive and although social distancing at 2 meters appears beneficial with regards to aerosol infectivity, in confined areas this is time limited requiring additional measures such as masks. The model shows the relative benefit of masks when social distancing is not possible at all times, or when in confined areas which can also be aided by efficient ventilation. Where a person is in one place for a prolonged period there is more risk requiring protection.
Conclusions Masks should be used in the above situations especially at an early stage of an outbreak. Public health planning requires stockpiling of masks and encouraging everyone to have suitable masks in their household when supplies are normalised. In the absence of widely available good quality masks the use of a cloth mask will be better than no protection at all.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
none this is a mathematical model and literature review no ethical approval is necessary .
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Spread sheet is available
